The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | Comparing haploSCT to other donor types in lymphoma treatment
Ali Bazarbachi, MD, PhD, American University of Beirut, Beirut, Lebanon, discusses the use of haploidentical stem cell transplantation (haploSCT) in treating non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). This approach allows all transplant-eligible patients to receive treatment, with post-transplant cyclophosphamide (PTCy) as graft-versus-host disease (GvHD) prophylaxis significantly improving outcomes. While haploSCT demonstrates promising results compared to cord blood and matched unrelated donors, in the context of PTCy-based prophylaxis, HLA-matched sibling donors have more favorable outcomes. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
